ICCR in Tokyo
This article was originally published in The Rose Sheet
Executive Summary
FDA will hold a public meeting Sept. 2 in College Park, Md. to prepare for International Cooperation on Cosmetics Regulations meeting being held Sept. 7 in Tokyo, Japan, according to pre-publication notice for the Federal Register. Meeting will be held to provide information and solicit comment in advance of ICCR steering committee and expert working group meetings. Those interested in participating must register with the FDA Office of the Commissioner. A coalition formed by regulatory authorities from the U.S., Canada, EU and Japan, ICCR aims to harmonize cosmetics regulations on global scale and lower barriers to trade while maintaining consumer protections (1"The Rose Sheet," Nov. 3, 2008, In Brief)
You may also be interested in...
International Cooperation on Alternative Test Methods
Alternative method validation organizations from U.S., EU and Japan, together with Health Canada, adopt framework for International Cooperation on Alternative Test Methods, announces European Center for the Validation of Alternative Methods (ECVAM). Initiative is product of September 2007 meeting of the International Cooperation on Cosmetics Regulation, which covered a range of issues including nanotechnology and good manufacturing practices (1"The Rose Sheet" Oct. 15, 2007, p. 4). ICCR also "recognized the importance of replacing, reducing and refining (less pain and distress) animal testing." Framework allows participating organizations to coordinate in designing validation studies, conducting scientific peer reviews and finally developing harmonized recommendations, according to ECVAM, which is joined by U.S. counterpart - the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) - as well as the Japanese Center for the Validation of Alternative Methods and a Canadian government rep. Under adopted schema, one validation organization will act as lead, drafting recommendations based on liaisons with others; if all parties are in agreement, they will finalize and forward recommendation to their respective regulatory authorities
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.